Company intelligence / Profile preview

Angel Pharma

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Angel Pharmaceuticals is a biopharmaceutical company focused on bringing innovative medicines to patients in China. Co-founded by ARCH Venture Partners, Amgen, and a group of seasoned biopharma executives, the company leverages a strategic partnership with Amgen to develop and commercialize a pipeline of high-potential assets. Its portfolio primarily targets oncology, inflammation, and autoimmune diseases, featuring advanced programs such as the KRAS G12C inhibitor sotorasib. Angel Pharmaceuticals aims to address significant unmet medical needs by combining global R&D excellence with local development expertise.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

AmgenARCH Venture Partners

Beyond the preview

Go deeper on Angel Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angel Pharma.

Explore the full profile